Tregalizumab
Humanized | |
|---|---|
| Target | CD4 |
| Clinical data | |
| Other names | BT-061 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Tregalizumab is an immunomodulator.[1] It is also known as BT-061. Tregalizumab binds to domain 2 of CD4,[2] and activates Regulatory T cells (Tregs).[3]
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- PMID 25512343.
- PMID 26834751.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |